PPIs significantly inhibited IL-13-induced eotaxin-3 expression in nasal epithelium, and patients with chronic rhinosinusitis (CRS) taking PPIs showed lower in vivo eotaxin-3 levels than those not taking PPIs (Min et al., 2017). The gene discussed is IL13; the disease is congenital rubella syndrome.